SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2 ; 11)(q37 ; q23)

• Type: Article in International Scientific Journal
• Date: 2006

Authors

cerveira, n (Author) Other; Correia, C (Author) Other; Bizarro, S (Author) Other; Pinto, C (Author) Other; Lisboa, S (Author) Other; Mariz, JM (Author) Other; Marques, M (Author) Other; Manuel R Teixeira (Author) ICBAS

Journal

Title: Oncogene

Vol. 25 No. 33

Pages: 6147-6152

ISSN: 0950-9232

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 34 Citations

Scopus - 36 Citations

Other information

Authenticus ID: P-004-9PN

DOI: 10.1038/sj.onc.1209626

Abstract (EN): We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2; 11)(q37; q23) as the only cytogenetic abnormality. Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL. RNA and DNA analyses showed the existence of an in-frame fusion of MLL exon 7 with SEPT2 exon 3, with the genomic breakpoints located in intron 7 and 2 of MLL and SEPT2, respectively. Search for DNA sequence motifs revealed the existence of two sequences with 94.4% homology with the topoisomerase II consensus cleavage site in MLL intron 7 and SEPT2 intron 2. SEPT2 is the fifth septin family gene fused with MLL, making this gene family the most frequently involved in MLL-related AML (about 10% of all known fusion partners). The protein encoded by SEPT2 is highly homologous to septins 1, 4 and 5 and is involved in the coordination of several key steps of mitosis. Further studies are warranted to understand why the septin protein family is particularly involved in the pathogenesis of MLL-associated leukemia.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6